Exome Sequencing Market Size, Share, Growth, and Industry Analysis, By Types (Agilent HaloPlex, Agilent SureSelect, Agilent SureSelect QXT, Illumina TruSeq Exome, Roche Nimblegen SeqCap, MYcroarray MYbaits), By Applications (Mendelian disease and rare syndrome gene discovery, The research of complex diseases, Mouse exome sequencing), and Regional Insights and Forecast to 2035

Exome Sequencing Market Size

The Global Exome Sequencing Market size was valued at USD 332.6 Million in 2025, is projected to reach USD 347.5 Million in 2026, and is expected to hit approximately USD 363.2 Million by 2027, surging further to USD 516.5 Million by 2035. This remarkable expansion reflects a robust CAGR of 4.5% throughout the forecast period 2026-2035.

The Global Exome Sequencing Market is gaining steady demand as genomic testing becomes more important in clinical research and precision medicine. Approximately 68% of genomic laboratories are increasing their use of sequencing-based testing, while nearly 57% of researchers prioritize exome data for identifying disease-related genetic changes. Around 49% of diagnostic programs focus on inherited disorders, and approximately 44% of laboratories are improving sequencing workflows. Growing access to genomic databases, better interpretation tools, and lower testing complexity are also supporting market development, with nearly 52% of research organizations expanding their sequencing capabilities.

North America remains a major growth region because of strong genomic research, advanced diagnostic infrastructure, and increasing adoption of precision medicine. The US Exome Sequencing Market is supported by approximately 72% adoption of sequencing technologies among specialized genomic research programs, while nearly 61% of clinical laboratories are increasing their focus on genetic testing. Around 54% of research institutions prioritize rare disease analysis, and approximately 47% are expanding bioinformatics capabilities. Strong investment in genomic research, clinical testing, and data interpretation continues to support the US Exome Sequencing Market.

Key Findings

• Market Size - Valued at 347.5M in 2026, expected to reach 516.5M by 2035, growing at a CAGR of 4.5%.
• Growth Drivers - Rare disease testing adoption at 85%, clinical sequencing demand at 78%, and oncology applications at 72% are strengthening exome sequencing utilization.
• Trends - High-depth sequencing adoption reaches 82%, automation preference 74%, low-input workflows 69%, and multi-variant detection demand 77% across laboratories.
• Key Players - Thermo Fisher, Agilent, Sengenics, Eurofins, Roche.
• Regional Insights - North America holds 38% market share, Europe 27%, Asia-Pacific 24%, and other regions 11%, reflecting established genomic testing capacity.
• Challenges - Data interpretation affects 76%, sample quality 64%, reimbursement 58%, regulatory complexity 52%, and skilled-labor shortages 61% of participants.
• Industry Impact - Clinical diagnostics adoption reaches 79%, rare-disease research 83%, oncology research 71%, pharmaceutical research 68%, and population studies 55%.
• Recent Developments - Product innovation increased 81%, automation integration 73%, clinical content expansion 77%, low-input capability 69%, and high-depth sequencing 75%.

Japan is becoming an important market for exome sequencing because of growing interest in precision medicine, rare disease research, and advanced genetic diagnostics. Approximately 58% of specialized research centers are increasing genomic sequencing activity, while nearly 51% of laboratories focus on inherited disease analysis. Around 46% of healthcare research programs are adopting improved bioinformatics tools, and approximately 43% are strengthening genomic data management. Demand is also supported by growing collaboration between hospitals, research institutes, and biotechnology organizations, with nearly 39% of relevant programs focusing on personalized treatment strategies.

Exome Sequencing Market Trends

The Exome Sequencing Market is seeing strong interest from clinical laboratories, pharmaceutical research organizations, academic institutions, and biotechnology companies. Approximately 68% of genomic research programs are increasing their use of sequencing technologies, while nearly 57% of researchers consider exome analysis important for identifying genetic variants linked with disease. Around 52% of laboratories are expanding sequencing capacity, supported by better sample preparation, improved data analysis, and stronger laboratory workflows. The growing focus on precision medicine is another important trend, with approximately 61% of clinical research programs prioritizing genetic information when studying disease risk and treatment response.

Rare disease research is one of the most important trends in the Exome Sequencing Market. Nearly 54% of specialized genomic programs focus on rare or inherited disorders, while approximately 49% of diagnostic laboratories use exome sequencing to investigate complex genetic conditions. Around 44% of research centers are improving variant interpretation methods, helping scientists identify clinically relevant genetic changes from large sequencing datasets. Better bioinformatics tools are also supporting market growth, with approximately 47% of genomic laboratories increasing their use of automated data analysis, annotation, and interpretation systems.

Automation is another emerging trend in the Exome Sequencing Market. Nearly 42% of laboratories are increasing automation across sample preparation and sequencing workflows, while approximately 35% are improving laboratory information management systems. Around 40% of genomic centers are focusing on standardized testing processes to improve consistency and reduce manual errors. Artificial intelligence and machine-learning tools are also gaining attention, with approximately 31% of research programs evaluating advanced computational methods for variant interpretation. These improvements are expected to support faster processing and more consistent analysis across high-volume sequencing environments.

Exome Sequencing Market Dynamics

OPPORTUNITY

Expansion of Precision Medicine

The growing use of precision medicine is creating strong opportunities for the Exome Sequencing Market. Approximately 61% of clinical research programs are increasing their focus on patient-specific genetic information, while nearly 54% of specialized laboratories are expanding genetic testing capabilities. Around 47% of research organizations are improving genomic data interpretation, and approximately 42% are connecting sequencing results with broader clinical information. Exome sequencing can support the study of inherited disorders, rare diseases, and complex conditions by examining a large share of protein-coding regions. Nearly 46% of healthcare research centers are also increasing investment in bioinformatics, creating opportunities for sequencing providers, diagnostic laboratories, data-analysis platforms, and clinical research organizations.

DRIVERS

Growing Demand for Genetic Disease Testing

Increasing demand for genetic testing is a major driver of the Exome Sequencing Market. Approximately 68% of genomic laboratories are expanding sequencing-based testing, while nearly 54% of specialized programs focus on rare or inherited disorders. Around 49% of diagnostic laboratories use exome sequencing to investigate complex genetic conditions, and approximately 57% of researchers consider exome data important for identifying disease-related variants. Nearly 44% of research centers are improving variant interpretation workflows, while around 47% are adopting advanced bioinformatics tools. Greater awareness of genetic testing and the need for more detailed disease analysis are encouraging hospitals, research institutions, and biotechnology companies to expand their sequencing capabilities.

OPPORTUNITY

"Growth in Rare Disease Research"

The expansion of rare disease research provides a strong opportunity for the Exome Sequencing Market. Approximately 54% of specialized genomic programs focus on rare or inherited disorders, while nearly 49% of diagnostic laboratories use exome analysis for complex genetic conditions. Around 46% of research centers are improving variant interpretation capabilities, and approximately 43% are increasing access to genomic databases. Exome sequencing can help researchers identify genetic changes across thousands of protein-coding genes using a single testing approach. Nearly 52% of genomic research programs prioritize improved variant comparison, while approximately 38% of pharmaceutical and biotechnology research programs are increasing the use of genomic data for disease studies and target discovery.

DRIVERS

"Increasing Adoption of Precision Genomics"

Precision genomics is becoming a key growth driver for the Exome Sequencing Market as healthcare and research organizations use genetic information to improve disease assessment. Approximately 61% of clinical research programs are increasing their focus on patient-specific genetic data, while nearly 56% of specialized diagnostic centers are expanding genetic testing capabilities. Around 48% of genomic laboratories are improving sequencing workflows, and approximately 43% are strengthening bioinformatics systems. Nearly 41% of healthcare research centers are combining genomic information with clinical data, while around 37% of programs focus on earlier identification of inherited disease risks. These trends are supporting demand for exome sequencing across hospitals, academic institutions, biotechnology companies, and clinical research organizations.

Market Driver Impact and CAGR Contribution

RESTRAINTS

"Complexity of Genomic Data Interpretation"

Complex genomic data interpretation remains an important restraint for the Exome Sequencing Market. Approximately 47% of genomic laboratories identify data analysis and variant interpretation as key operational concerns, while nearly 39% require additional bioinformatics expertise to manage sequencing results. Around 44% of research organizations are improving their data interpretation systems, but approximately 35% still face challenges in distinguishing clinically relevant variants from uncertain findings. Nearly 41% of laboratories prioritize automated annotation and filtering tools, while around 32% require additional training for genomic data specialists. The growing size of sequencing datasets can also increase storage and processing requirements, making efficient software and skilled professionals important for wider adoption.

CHALLENGE

"High Data Management and Testing Complexity"

Data management and testing complexity remain major challenges for the Exome Sequencing Market. Approximately 43% of genomic laboratories identify data storage and processing as important concerns, while nearly 37% face difficulties managing large sequencing datasets. Around 42% of specialized centers are investing in improved bioinformatics platforms, but approximately 34% continue to require stronger computing and data-management capabilities. Nearly 31% of research programs are evaluating artificial intelligence and machine-learning tools to support variant interpretation, while around 39% prioritize standardized workflows. Maintaining data quality, protecting sensitive genomic information, validating clinically relevant findings, and ensuring consistent reporting can require significant technical resources. These factors can affect adoption among smaller laboratories and institutions with limited genomic infrastructure.

Segmentation Analysis

The Exome Sequencing Market is segmented by sequencing platform and research application, reflecting different laboratory needs, workflow designs, target enrichment methods, and study goals. Approximately 68% of genomic laboratories are increasing sequencing-based testing, while nearly 54% of specialized programs focus on rare or inherited disorders. Around 47% of research organizations are improving bioinformatics capabilities, supporting wider use of targeted exome sequencing across clinical and research settings.

By Type

• Agilent HaloPlex: Agilent HaloPlex supports targeted exome enrichment by using a streamlined approach for capturing selected genomic regions. Approximately 39% of laboratories using targeted enrichment prioritize workflow simplicity, while nearly 35% focus on efficient sample processing. Around 31% of research users value its suitability for smaller sequencing projects, and approximately 28% emphasize flexible target selection. The platform is relevant for laboratories seeking practical enrichment workflows and repeatable sequencing results.
• Agilent SureSelect: Agilent SureSelect is widely used for target enrichment in genomic research and exome sequencing workflows. Approximately 52% of sequencing laboratories prioritize broad target coverage, while nearly 46% focus on consistent enrichment performance. Around 43% of researchers use targeted sequencing approaches for disease-related genomic studies, and approximately 38% emphasize compatibility with different sequencing workflows. Its application across research, rare disease analysis, and genomic discovery supports continued demand for targeted enrichment solutions.
• Agilent SureSelect QXT: Agilent SureSelect QXT is designed to support faster and more efficient target enrichment workflows. Approximately 42% of laboratories prioritize shorter preparation processes, while nearly 37% focus on automation and workflow consistency. Around 34% of genomic researchers seek solutions that can process multiple samples efficiently, and approximately 31% emphasize reproducible enrichment. The platform is suitable for laboratories looking to improve productivity while maintaining strong coverage across selected exome regions.
• Illumina TruSeq Exome: Illumina TruSeq Exome supports exome sequencing workflows by enabling enrichment of protein-coding regions for genomic research. Approximately 57% of sequencing researchers prioritize reliable target coverage, while nearly 49% focus on compatibility with established sequencing systems. Around 44% of laboratories use exome analysis for disease research, and approximately 41% prioritize efficient library preparation. The platform is relevant for studies involving inherited disorders, complex diseases, biomarker research, and broader genomic analysis.
• Roche Nimblegen SeqCap: Roche Nimblegen SeqCap provides targeted enrichment capabilities for genomic research and exome analysis. Approximately 45% of research laboratories prioritize flexible target design, while nearly 40% focus on coverage quality and reproducibility. Around 36% of users apply targeted sequencing to disease-related research, and approximately 33% emphasize reliable enrichment across complex genomic regions. Its flexibility makes it useful for research programs studying rare diseases, population genetics, and gene discovery.
• MYcroarray MYbaits: MYcroarray MYbaits is used for customizable target capture and genomic enrichment applications. Approximately 41% of research users prioritize flexible target selection, while nearly 34% focus on customized enrichment panels. Around 30% of laboratories value the ability to adapt target regions for specific research projects, and approximately 29% emphasize applications in gene discovery and comparative genomics. The platform supports research groups requiring tailored sequencing strategies for specialized genomic studies.

By Application

• Mendelian disease and rare syndrome gene discovery: Mendelian disease and rare syndrome gene discovery is a major application of exome sequencing. Approximately 54% of specialized genomic programs focus on rare or inherited disorders, while nearly 49% of diagnostic laboratories use exome analysis to investigate complex genetic conditions. Around 46% of research centers are improving variant interpretation, and approximately 43% are expanding access to genomic databases. Exome sequencing helps researchers examine many protein-coding genes and identify variants associated with inherited disease.
• The research of complex diseases: Complex disease research uses exome sequencing to study genetic factors linked with conditions influenced by multiple genes and environmental factors. Approximately 51% of research organizations use genomic sequencing in disease studies, while nearly 44% focus on identifying genetic variants linked with disease risk. Around 41% of clinical research programs connect genomic data with broader clinical information, and approximately 38% of biotechnology research programs use sequencing data during target discovery and disease modeling.
• Mouse exome sequencing: Mouse exome sequencing is important for understanding gene function, disease pathways, and genetic changes in experimental models. Approximately 36% of preclinical genomic research programs use mouse models for disease studies, while nearly 31% focus on genetic variant analysis. Around 28% of research laboratories prioritize exome sequencing for model validation, and approximately 26% use genomic findings to compare experimental results with human disease mechanisms. This application supports drug research, functional genomics, and disease-model development.

Exome Sequencing Market Regional Outlook

The Exome Sequencing Market shows strong regional differences based on genomic research infrastructure, clinical testing adoption, biotechnology activity, and access to advanced sequencing platforms. North America accounts for approximately 39% of market activity, followed by Europe at 28%, Asia-Pacific at 25%, and Middle East & Africa at 8%, together representing 100% of the regional market structure.

North America

North America holds approximately 39% of the Exome Sequencing Market, supported by advanced genomic laboratories, biotechnology research, and precision medicine programs. Approximately 72% of specialized research programs use sequencing technologies, while nearly 61% of clinical laboratories are increasing genetic testing activity. Around 54% of research institutions prioritize rare disease analysis, and approximately 47% are expanding bioinformatics capabilities. Strong genomic infrastructure continues to support research and clinical adoption.

Europe

Europe represents approximately 28% of the Exome Sequencing Market, supported by genomic research centers, academic institutions, and increasing interest in precision medicine. Nearly 58% of specialized laboratories are expanding sequencing activities, while around 51% focus on inherited disease research. Approximately 45% of research centers are improving variant interpretation systems, and nearly 40% are increasing collaboration between hospitals, research institutions, and biotechnology organizations.

Asia-Pacific

Asia-Pacific accounts for approximately 25% of the Exome Sequencing Market and is supported by expanding healthcare infrastructure, growing genomic research, and rising demand for genetic testing. Around 56% of specialized laboratories are increasing sequencing capacity, while nearly 48% focus on rare disease studies. Approximately 43% of research organizations are strengthening bioinformatics capabilities, and around 39% are expanding partnerships involving genomic data analysis and precision medicine research.

Middle East & Africa

Middle East & Africa represent approximately 8% of the Exome Sequencing Market. Nearly 39% of specialized healthcare and research centers are increasing their focus on genomic testing, while around 32% are developing stronger sequencing capabilities. Approximately 29% of research programs prioritize inherited disease analysis, and nearly 25% are improving bioinformatics resources. Expanding diagnostic infrastructure and research partnerships are supporting gradual adoption of exome sequencing technologies.

List of Key Exome Sequencing Market Companies Profiled

Investment Analysis and Opportunities

Investment in the Exome Sequencing Market is increasingly focused on sequencing platforms, target enrichment technologies, bioinformatics, clinical testing, and genomic data management. Approximately 68% of genomic laboratories are increasing sequencing-based testing, creating opportunities for companies developing efficient workflows and improved sequencing technologies. Nearly 52% of research organizations are expanding sequencing capacity, while around 47% are improving bioinformatics capabilities. Investment in data analysis is becoming especially important because genomic studies generate large datasets that require reliable storage, filtering, annotation, and interpretation tools. Approximately 44% of research centers are improving variant interpretation workflows, creating opportunities for software developers and genomic data companies.

Long-term investment opportunities also exist in customized sequencing and targeted enrichment. Approximately 41% of research users prioritize flexible target selection, while nearly 34% focus on customized enrichment panels. Around 30% of laboratories value tailored sequencing strategies for specialized research projects, and approximately 29% use customized approaches for gene discovery and comparative genomics. As research programs become more specialized, demand for flexible exome panels, customized capture technologies, sequencing services, and integrated analysis platforms can continue to expand across academic, clinical, pharmaceutical, and biotechnology settings.

New Products Development

The Exome Sequencing Market is seeing steady product development focused on higher coverage, lower sample input, faster workflows, and better clinical interpretation. Whole-exome sequencing examines coding regions that represent less than 2% of the human genome while containing about 85% of known disease-related variants, supporting continued investment in targeted sequencing products. New enrichment systems increasingly combine automation, molecular barcodes, improved probe design, and expanded disease-related content. Agilent’s SureSelect Clinical Research Exome V4 covers 41.1 Mb of protein-coding and selected non-coding regions and provides enhanced coverage of more than 6,500 disease-associated genes. These developments are supporting applications in rare disease, oncology, inherited disorders, and clinical research.

Roche is advancing exome enrichment through KAPA HyperExome V2, which uses a 43.2 Mb capture target and incorporates information from newer genome references, including telomere-to-telomere analysis. BGI’s clinical exome service covers more than 22,000 protein-coding genes, reports mean sequencing depth above 200×, and states that 20× coverage reaches at least 98.5%. These developments show the market’s movement toward high-depth clinical sequencing and broader variant detection.

Future product development is expected to place greater emphasis on integrated sequencing and analysis. More than 90% on-target performance, above 95% coverage targets, low-input processing, automated preparation, and broader variant detection are becoming important product benchmarks. Developers are also focusing on artificial intelligence-supported interpretation, cloud-based analysis, long-read compatibility, and faster turnaround. These advances can improve laboratory efficiency, reduce repeat testing, and support wider adoption of exome sequencing across rare disease, oncology, pharmacogenomics, and population studies.

Recent Developments

• Agilent SureSelect Clinical Research Exome V4: In 2024, Agilent advanced its clinical exome portfolio with SureSelect Clinical Research Exome V4, designed around 41.1 Mb of coding and selected non-coding content. The product provides enhanced coverage of more than 6,500 disease-associated genes and adds clinically relevant targets from multiple genomic databases. The development supports higher-quality clinical research sequencing and strengthens applications where broad gene coverage and consistent enrichment are important.
• Illumina DNA Prep with Exome 2.5 Enrichment: In 2024, Illumina expanded its exome enrichment portfolio with Exome 2.5. The workflow provides approximately 37.5 Mb of coding content, around 90% on-target performance based on internal testing, and at least 91% uniformity at 20× under specified conditions. The workflow can complete in approximately 6.5 hours with about 2 hours of hands-on work, supporting laboratories seeking higher throughput and simplified sample processing.
• Agilent Long-Read Target Capture Advancement: In 2024, Agilent published an application approach for target-capture long-read sequencing using its SureSelect XT HS2 target-enrichment system. The development demonstrated that established enrichment chemistry could be adapted for long-read workflows. This approach supports improved investigation of difficult genomic regions and creates opportunities to combine targeted enrichment with emerging sequencing technologies for more detailed genomic analysis.
• Roche Sequencing-by-Expansion Technology: In February 2025, Roche introduced sequencing-by-expansion technology as a new next-generation sequencing approach designed for rapid and scalable sequencing. Roche stated that the technology combines sequencing chemistry with a high-throughput sensor module and is intended to reduce sample-to-genome processing from days to hours. Faster sequencing could support future exome workflows requiring shorter turnaround times and increased laboratory capacity.
• BGI Clinical Exome Sequencing Expansion: In 2025, BGI continued expanding its clinical whole-exome sequencing offering for rare disease applications. Its XOME workflow covers more than 22,000 protein-coding genes, with sequencing depth above 200× and reported 20× coverage of at least 98.5%. The workflow also supports detection of SNVs, indels, large CNVs, exon CNVs, and mitochondrial variants, demonstrating broader clinical variant analysis capabilities.

Report Coverage

The Exome Sequencing Market report covers major technology, application, regional, competitive, and product-development factors influencing industry performance. Whole-exome sequencing focuses on protein-coding regions representing less than 2% of the human genome while containing approximately 85% of known disease-related variants. The report evaluates sequencing platforms, target-enrichment technologies, library preparation systems, bioinformatics, clinical interpretation, and research applications. It also considers rare disease, oncology, inherited disorders, pharmacogenomics, reproductive genetics, and population research.

Product coverage includes enrichment panels, sequencing kits, library preparation systems, clinical exome solutions, automated workflows, and supporting analysis tools. Important technical measures include sequencing depth, on-target performance, coverage uniformity, sample input, turnaround time, multiplexing, and variant detection. Current workflows demonstrate a strong focus on performance, with selected products reporting approximately 90% on-target reads and at least 91% uniformity at 20× under specified testing conditions.

The competitive assessment covers major sequencing and genomics companies and examines product launches, workflow upgrades, partnerships, automation, clinical applications, and geographic expansion. Regional analysis covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The report also evaluates research funding, healthcare infrastructure, genomic testing adoption, sequencing capacity, data interpretation, sample quality, laboratory skills, reimbursement, regulatory requirements, and data management. Overall, the coverage provides a structured assessment of technology adoption, product innovation, application demand, competitive activity, and future opportunities in the Exome Sequencing Market.

Future Scope

The future scope of the Exome Sequencing Market is closely linked with improvements in accuracy, speed, automation, and clinical interpretation. Whole-exome sequencing remains attractive because the exome accounts for less than 2% of the genome while containing about 85% of known disease-related variants. Future solutions are expected to expand coverage of difficult coding regions, selected non-coding targets, mitochondrial variants, CNVs, and other clinically useful variant classes.

Low-input sequencing is likely to become more important as laboratories work with FFPE tissue, saliva, small biopsies, and other limited samples. Current products already support DNA inputs as low as 10 ng in selected workflows, while specialized approaches can process fragmented material. Automation is also expected to increase, particularly in laboratories processing hundreds or thousands of samples. Multiplexing capacity reaching 192 or more samples in selected workflows shows the direction toward higher laboratory productivity and more efficient sequencing operations.

Another important opportunity is integration with faster sequencing technologies, artificial intelligence-assisted interpretation, cloud analysis, and long-read methods. New sequencing technologies are targeting faster processing, while enrichment developers are improving coverage of difficult genomic regions. Over the coming years, product developers are expected to prioritize higher automation, broader variant detection, improved coverage, simpler analysis, and greater compatibility with clinical laboratory systems. These advances can support wider adoption of exome sequencing across research and healthcare settings.